The overall survival rate was significantly higher in those with low expression of CCN1 compared to that in the high expression group among lung squamous cell carcinoma (LUSC) (Figure 7C) as well as bladder urothelial cancer (BLCA) and stomach adenocarcinoma (STAD) patients (Figure 7—figure supplement 1A,C). The gene discussed is CCN1; the disease is gastric adenocarcinoma.